Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

494 results

• Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?: Complete Statistical AnalysisIndependent statistical analysis of Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 71NCT03541980
• Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 3NCT01875237
• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 17NCT02458235
• Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 6NCT00625729
• Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 50NCT00303667
• Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: Complete Statistical AnalysisIndependent statistical analysis of Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 27NCT02248597
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 14NCT01093586
• Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 31NCT00963872
• Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 12NCT00295880
• Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients: Complete Statistical AnalysisIndependent statistical analysis of Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 11NCT03186677
• Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis: Complete Statistical AnalysisIndependent statistical analysis of Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 82NCT00762073
• Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin’s Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 68NCT00184002
• DREAMM-3Independent statistical analysis of DREAMM-3, a randomized phase 3 trial comparing single-agent belantamab mafodotin with pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.Phase 3Results postedn = 325NCT04162210
• DREAMM-7Independent statistical analysis of the DREAMM-7 phase 3 China subpopulation trial evaluating belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma.Phase 3Results postedn = 72NCT06868654
• DREAMM-8Independent statistical analysis of DREAMM-8, a randomized phase 3 trial of belantamab mafodotin plus pomalidomide and dexamethasone versus bortezomib plus pomalidomide and dexamethasone in multiple myeloma.Phase 3Results postedn = 21NCT06956170
• DUS on the Prescribing Indications for CPA/EE in 5 European Countries: Complete Statistical AnalysisIndependent statistical analysis of DUS on the Prescribing Indications for CPA/EE in 5 European Countries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 1,597NCT02494297
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 43NCT01692197
• ECHELON-2Independent statistical analysis of ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 452NCT01777152
• Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 24NCT01702246
• Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 17NCT04046263
• Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels: Complete Statistical AnalysisIndependent statistical analysis of Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04537715).Phase 1Results postedn = 42NCT04537715
• Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01100658).Phase NAResults postedn = 1NCT01100658
• Effects of Transfusion of Older Stored Red Cells: Complete Statistical AnalysisIndependent statistical analysis of Effects of Transfusion of Older Stored Red Cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534676).Phase NAResults postedn = 3NCT01534676
• Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 13NCT01703169
• Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 29NCT00802737
• Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): primary endpoint results, effect estimate…Phase 3Results postedn = 49NCT01438840
• Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden: primary endpoint results, effect estimate…Phase 3Results postedn = 184NCT03263091
• Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 54NCT01369498
• Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 18NCT00520494
• Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 66NCT00157157
• Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 216NCT00708435
• Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan: primary endpoint results, effect estimate with…Phase 3Results postedn = 323NCT03439137
• Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan: primary endpoint results, effect estimate with…Phase 3Results postedn = 24NCT03461146
• Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 129NCT03738423
• EFforT-BCRLIndependent statistical analysis of Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02609724).Phase NAResults postedn = 194NCT02609724
• ELARAAn independent statistical analysis of the phase 2 ELARA trial of tisagenlecleucel in adults with refractory or relapsed follicular lymphoma, covering trial design, the primary complete response endpoint, planned statistical analysis, safety,…Phase 2Results postedn = 98NCT03568461
• ELARAIndependent statistical analysis of Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 98NCT03568461
• ELEVATEIndependent statistical analysis of Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 292NCT00678587
• Eltrombopag for Fanconi Anemia: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag for Fanconi Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03206086).Phase 2Results postedn = 25NCT03206086
• Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2/3Results postedn = 21NCT01428635
• Eltrombopag Phase III Study In Chinese Chronic ITP Patients: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Phase III Study In Chinese Chronic ITP Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01762761).Phase 3Results postedn = 155NCT01762761
• EmiandMeIndependent statistical analysis of An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 30NCT04723693
• Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05282459).Phase 1/2Results postedn = 17NCT05282459
• ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.Phase 3Results postedn = 929NCT01568866
• ENESTopAn independent statistical analysis of the phase 2 ENESTop trial of nilotinib cessation after sustained MR4.5 in chronic myeloid leukemia, including its single-group design, treatment-free remission endpoint, planned statistical approach, reported safety…Phase 2Results postedn = 163NCT01698905
• ENESTPathIndependent statistical analysis of A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.: primary endpoint results, effect estimate…Phase 3Results postedn = 620NCT01743989
• ENHANCEIndependent statistical analysis of Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 539NCT04313881
• Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 66NCT01796470
• EPICIndependent statistical analysis of Mechanisms of EPO-induced Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03810911).Phase 2Results postedn = 27NCT03810911
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 31NCT00400686

← All therapeutic areas